Lanting Capital

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 12
Average round size
The average size of a deal this fund participated in
Portfolio companies 12
Lead investments 2
Exits 1
Key employees 2
Stages of investment

Areas of investment

  • Robotics
  • Internet of Things
  • Artificial Intelligence
  • Internet
  • Medical

The venture was found in Asia in China. The main office of represented VC is situated in the Hangzhou.

Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Lanting Capital performs on 18 percentage points less the average number of lead investments. The top activity for fund was in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Lanting Capital, startups are often financed by Shunwei Capital, Yunmu Capital, Xiaomi. The meaningful sponsors for the fund in investment in the same round are Yunqi Partners, Xiaomi, Tencent Holdings. In the next rounds fund is usually obtained by Yunmu Capital, Yihang Funds, Yao Capital.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Yunji Technology, DeepTech, Emotech LTD Among the most popular fund investment industries, there are Education, Robotics. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Lanting Capital:
Typical Co-investors
Lanting Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Lanting Capital:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Rona Therapeutics

Health Care
$33M07 Apr 2022 Shanghai, Shanghai, China

Regor Therapeutics

$90M18 Feb 2021 Boston, Massachusetts, United States


Clinical Trials
31 Dec 2020 Futian District, Guangdong Province, China

Green Rice Technology

Internet of Things
$20M06 Dec 2018 Futian District, Guangdong Province

MIT Technology Review

Digital Media
$3M10 Nov 2018 China, Beijing


Information Technology
$15M28 Feb 2018 Dongcheng District, Beijing, China

Lumi United Technology

Home Services
Internet of Things
Smart Home
$15M04 Jan 2018 Futian District, Guangdong Province

Yunji Technology

Service Industry
21 Nov 2017 Dongcheng District, Beijing, China


Artificial Intelligence
Autonomous Vehicles
12 Oct 2017 China, Shanghai
Regor Therapeutics Announces Completion of $90 Million Series B Financing

– Regor Therapeutics announced the successful completion of $90m Series B financing.
– The round was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China.
– Regor Therapeutics was established with initial series A strategic investment from Qilu Pharmaceutical Group, a well-known Chinese pharmaceutical company.
– Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development.
– Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Lanting Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: